FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
ProQR Therapeutics NV FCF Yield % Related Terms
ProQR Therapeutics NV FCF Yield % Historical Data
* Premium members only.
The historical data trend for ProQR Therapeutics NV's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:PRQRN vs GALT, HRTX, PLYX: FCF Yield % Comparison
For the Biotechnology subindustry, ProQR Therapeutics NV's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProQR Therapeutics NV FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's FCF Yield % distribution charts can be found below:
* The bar in red indicates where ProQR Therapeutics NV's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProQR Therapeutics NV (MEX:PRQRN) has a FCF Yield % of -29.89 as of Jun. 25, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on ProQR Therapeutics NV and its competitors. According to the industry distribution chart, ProQR Therapeutics NV ranks #1061 out of 1418 companies in the Biotechnology industry, placing it in the top 74.8%.
Is ProQR Therapeutics NV's FCF Yield % too high?
ProQR Therapeutics NV's current FCF Yield % is -29.89. Based on the distribution chart, ProQR Therapeutics NV ranks #1061 out of 1418 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ProQR Therapeutics NV has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does ProQR Therapeutics NV's FCF Yield % compare to GALT and HRTX?
According to the Biotechnology industry distribution chart, ProQR Therapeutics NV ranks #1061 out of 1418 companies for FCF Yield %. This places ProQR Therapeutics NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on ProQR Therapeutics NV and its competitors. ProQR Therapeutics NV's current FCF Yield % is -29.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProQR Therapeutics NV stock overvalued right now?
ProQR Therapeutics NV (MEX:PRQRN) has a current FCF Yield % of -29.89. The stock's GF Value™ is MXN40.07, compared to a current price of MXN36.00 — trading 10.2% below its estimated fair value. The current FCF Yield % is -29.89. ProQR Therapeutics NV's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For ProQR Therapeutics NV (MEX:PRQRN), the current FCF Yield % is -29.89 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ProQR Therapeutics NV (MEX:PRQRN) Overvalued in 2026?
Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued.
The current stock price of MXN36.00 is trading 10.2% below its estimated GF Value™ of MXN40.07.
Key valuation signals for MEX:PRQRN:
FCF Yield %: -29.89
GF Value™: MXN40.07 vs. price of MXN36.00 (10.2% below fair value)
No single metric tells the full story. See the MEX:PRQRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
44GF Score
Get the complete analysis for MEX:PRQRN
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PRQRN has been successfully added to your 
